Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sucampo Pharmaceuticals, Inc. (SCMP - Snapshot Report) commenced a global pivotal phase III study for Amitiza in pediatric functional constipation.

 

The phase III program has two similar designed well-controlled pivotal studies. The first part of the study, which has already commenced, is a randomized, placebo-controlled, double-blind study which evaluates the efficacy, safety and pharmacokinetics of Amitiza in pediatric patients aged 6 to 17 years. The other part will evaluate Amitiza liquid formulation in patients aged 6 months to below 6 years.

The first part will enroll more than 500 pediatric functional constipation patients which will be treated for 12 weeks with weight-based dosages of 12 mcg or 24 mcg twice daily (BID). The primary endpoint of the study is the overall spontaneous bowel movement (SBM) response.

The long-term safety of Amitiza will also be evaluated in two open-label extension studies. Sucampo notes that functional constipation has seen an approximately 300% rise in the U.S. over the last 10 years. A supplemental new drug application (sNDA) is expected to be filed with the U.S. Food and Drug Administration (FDA) by early2016.

We note that Amitiza was approved by the FDA in 2006 for chronic idiopathic constipation (CIC) in adults. Then, it gained FDA approval in 2008 for irritable bowel syndrome with constipation (IBS-C) in women aged above 18 years. Furthermore, it gained FDA approval for opioid-induced constipation (OIC) in Apr 2013. Amitiza is approved for CIC in Switzerland as well as the UK and for chronic constipation (CC) in Japan. 

Sucampo carries a Zacks Rank #1 (Strong Buy). Some equally ranked stocks include Questcor Pharmaceuticals Inc. (QCOR - Analyst Report), Actelion Ltd. (ALIOF) and Jazz Pharmaceuticals plc (JAZZ - Analyst Report), each carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%